Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Maiko Niki

Neutrophil-To-Lymphocyte Ratio as an Early Marker of Outcomes in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Nivolumab

International Journal of Clinical Oncology

English

Immunohistochemical Analysis of NANOG Expression and Epithelial-Mesenchymal Transition in Pulmonary Sarcomatoid Carcinoma

English

Related publications

P2.01-112 Prognostic Value of Changes in Neutrophil-To-Lymphocyte Ratio in Patients With Lung Cancer Treated With Nivolumab

Journal of Thoracic Oncology

English

Neutrophil-Lymphocyte Ratio Predicts Recurrence in Patients With Resected Stage 1 Non-Small Cell Lung Cancer

Journal of Cardiothoracic Surgery

Cardiology

Cardiovascular Medicine

English

Neutrophil/Lymphocyte Ratio Predicts Chemotherapy Outcomes in Patients With Advanced Colorectal Cancer

British Journal of Cancer

Cancer Research

Oncology

2011

English

Baseline Neutrophil-To-Lymphocyte Ratio (NLR) and Derived NLR Could Predict Overall Survival in Patients With Advanced Melanoma Treated With Nivolumab

Journal for ImmunoTherapy of Cancer

English

The Prognostic Impact of Neutrophil-To-Lymphocyte Ratio, Lymphocyte-To-Monocyte Ratio, and Platelet-To-Lymphocyte Ratio in Patients With Advanced Colorectal Cancer Treated With First-Line Chemotherapy

Przeglad Gastroenterologiczny

Gastroenterology

2018

English

MA10.06 Impact of Immune-Related Adverse Events on Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab

Journal of Thoracic Oncology

English

Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non‐Small Cell Lung Cancer Patients

English

Pseudo-Progression and the Neutrophil-To-Lymphocyte Ratio in Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors: A Case–Control Study

OncoTargets and Therapy

Oncology

Pharmacology

2019

English

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Maiko Niki

Neutrophil-To-Lymphocyte Ratio as an Early Marker of Outcomes in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Nivolumab

Immunohistochemical Analysis of NANOG Expression and Epithelial-Mesenchymal Transition in Pulmonary Sarcomatoid Carcinoma

Related publications

P2.01-112 Prognostic Value of Changes in Neutrophil-To-Lymphocyte Ratio in Patients With Lung Cancer Treated With Nivolumab

Neutrophil-Lymphocyte Ratio Predicts Recurrence in Patients With Resected Stage 1 Non-Small Cell Lung Cancer

Neutrophil/Lymphocyte Ratio Predicts Chemotherapy Outcomes in Patients With Advanced Colorectal Cancer

Baseline Neutrophil-To-Lymphocyte Ratio (NLR) and Derived NLR Could Predict Overall Survival in Patients With Advanced Melanoma Treated With Nivolumab

The Prognostic Impact of Neutrophil-To-Lymphocyte Ratio, Lymphocyte-To-Monocyte Ratio, and Platelet-To-Lymphocyte Ratio in Patients With Advanced Colorectal Cancer Treated With First-Line Chemotherapy

MA10.06 Impact of Immune-Related Adverse Events on Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab

Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non‐Small Cell Lung Cancer Patients

Pseudo-Progression and the Neutrophil-To-Lymphocyte Ratio in Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors: A Case–Control Study

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab